BPC-157 dosage chart
5 mg Vial
BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.
- Typical daily range
- 200–600 mcg once daily (gradual titration).
- Easy measuring
- At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Injection frequency
- Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
- Dosing schedule
- 5 days on / 2 days off: dose Monday through Friday, then take Saturday and Sunday off. That is 5 dosing days per week.
Route:
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing Cycle & Timing
This protocol runs on a 5 days on / 2 days off cycle.
- Cycle: 5 days on, 2 days off — dose Monday through Friday and rest on the weekend.
- 5 dosing days per week; the 2 off days help limit receptor desensitisation and give injection sites time to recover.
- Keep the dose time consistent on dosing days.
- If a weekday dose is missed, take it the same day if possible — do not dose on an off day to catch up.
- Weekly totals in the supplies and shopping lists are calculated on 5 dosing days, not 7.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.
How This Works
BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data are not yet available.
Potential Benefits & Side Effects
Observations from preclinical and early clinical literature.
- Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
- Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
- Phase I safety studies report good tolerability with no serious adverse events at tested doses.
- Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
- Long-term human safety and efficacy remain under investigation.
Lifestyle Factors
Complementary strategies for best outcomes.
- Support recovery with adequate protein intake and micronutrient-rich foods.
- Balance activity and rest to allow tissue adaptation without overuse.
- Prioritize sleep and stress management to enhance natural healing processes.
- Consult qualified healthcare providers for injury-specific rehabilitation guidance.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Discard used syringes immediately in a sharps container per WHO guidelines.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. BPC-157 remains investigational with limited human clinical data.
Supplies needed
Plan covers the full 8-week protocol at the lowest listed starting dose: 0.2 mg per dose, 5 days on / 2 days off (40 administrations in total), using 5 mg vials. After mixing with 3 mL, the concentration is 1.67 mg/mL and each dose requires 0.12 mL total.
BPC-157 vials (5 mg each)
Vials are rounded up only after calculating the whole protocol: ceil(8 ÷ 5) = 2. Usable peptide remaining in an opened vial carries forward to the next dose.
- Full protocol (8 weeks)
- 2 vials (8 mg needed ÷ 5 mg)
Insulin syringes (U-100, 1 mL)
One fresh syringe per administration.
- Full protocol (8 weeks)
- 40 syringes
Bacteriostatic water (10 mL bottles)
Use 3 mL per vial for reconstitution (2 × 3 mL = 6 mL).
- Full protocol (8 weeks)
- 1 × 10 mL bottle
Alcohol swabs
One for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box.
- Full protocol (8 weeks)
- 80 swabs
| Supply | Full protocol (8 weeks) |
|---|---|
| BPC-157 vials (5 mg each)Vials are rounded up only after calculating the whole protocol: ceil(8 ÷ 5) = 2. Usable peptide remaining in an opened vial carries forward to the next dose. | 2 vials (8 mg needed ÷ 5 mg) |
| Insulin syringes (U-100, 1 mL)One fresh syringe per administration. | 40 syringes |
| Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (2 × 3 mL = 6 mL). | 1 × 10 mL bottle |
| Alcohol swabsOne for the vial stopper per draw + one for each injection site (5 days on / 2 days off). Recommend 1 × 100-count box. | 80 swabs |
BPC-157 dosage FAQs
How much bacteriostatic water do you use to reconstitute BPC-157?
Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration. for a 5 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
How often is BPC-157 administered in research protocols?
Injection frequency: Once daily — 5 days on, 2 days off (dose Mon–Fri, rest Sat–Sun).
What does the BPC-157 route: look like?
Weeks 1–2 — 200 mcg (0.2 mg) — 12 units (0.12 mL); Weeks 3–4 — 400 mcg (0.4 mg) — 24 units (0.24 mL); Weeks 5–8+ — 600 mcg (0.6 mg) — 36 units (0.36 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for BPC-157?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted BPC-157 be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a BPC-157 dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is BPC-157 approved for human use?
No. BPC-157 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.